Perampanel

Drug Profile

Perampanel

Alternative Names: E-2007; ER-155055-90; Fycompa

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ESTEVE
  • Class Analgesics; Antiepileptic drugs; Nitriles; Pyridines; Pyridones; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Seizures
  • Phase II Epilepsy
  • Discontinued Migraine; Multiple sclerosis; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 10 May 2017 Phase-III clinical trials in Partial epilepsies (Monotherapy) in Japan (PO) before May 2017 (Eisai pipeline, May 2017)
  • 22 Apr 2017 Long term efficacy and safety data from an Expanded Access Programme for Tonic-clonic seizures presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 10 Mar 2017 Registered for Partial epilepsies (Adjunctive treatment, In adolescents, In adults) in South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top